Do people under 30 die at above normal rates for weeks after mRNA injections?

Guest Post by Alex Berenson

Comprehensive data from New Zealand suggest they do

National vaccine monitoring data from New Zealand show Pfizer’s mRNA Covid shot is associated with above-normal death rates in teenagers and young adults for weeks after they are jabbed.

The signal is subtle and does not prove the vaccines are behind the extra deaths. But they are another warning sign for the mRNA vaccines, which are already known to increase the risk of myocarditis in young men and have effectively no benefit for healthy young people in any case.

Yet colleges such as New York University continue to mandate booster shots for students.

New Zealand’s Ministry of Health publishes regular and detailed reports on Covid vaccine safety, including specific lists of adverse events it has received.

As part of the reports, the ministry also counts all deaths of people who have received the jabs in the previous 21 days. (If other countries provide a similarly comprehensive post-shot death count, I’m not aware of them.)

New Zealand has a national Covid immunization registry and a national death registry, so the records and matching should largely be accurate, though the ministry warns that they will take “many weeks” to be complete.

The ministry breaks down the deaths by age, ranging from 0-9 through over 80. It then compares the actual number of people who died in the three weeks after the shots to the “expected” number. That figure is simply the number of deaths demographers would have expected over a random three-week period based on actuarial tables estimating mortality.

For older age ranges, the charts reveal a striking trend – “observed” deaths of vaccine recipients are far below the number of expected deaths for the first three weeks after vaccination.

In general, vaccinated people over the age of 30 had roughly 40 to 55 percent lower death rates than the unvaccinated over that period. They had that apparent benefit after both doses and the booster.

To be clear, this gap does NOT suggest that the mRNA vaccines reduce all-cause deaths. No one, not even the most fanatical vaccine advocate, would suggest they do. In the clinical trials of mRNA vaccines, all-cause deaths were almost exactly balanced between vaccine and placebo recipients.

Rather, the large gap between the actual and expected rates is evidence of a well-known epidemiological phenomenon called “healthy vaccine user bias.”

This bias takes many forms, but one is that physicians are unlikely to offer vaccines to people – at any age – near the end of their lives. As the ministry of health itself notes:

One reason for the number of deaths in the vaccinated group appearing to be lower could be that healthcare professionals of extremely frail patients give the advice not to get vaccinated.

—

But for people under 30, and especially between 10 and 19, the data present a very different picture.

Not only were deaths not lower in vaccinated people in those age ranges in the three weeks after the shot, they were actually higher after the first dose. The shift between the under 30 and over 30 groups is remarkable. (The fact no one under 10 is included in the “observed death” category may represent reporting lag.)

SOURCE

The higher death rates continued for people under 20 after the second dose, though not for people between 20 and 30.

So what’s specifically behind the deaths? At this point we don’t know.

Unfortunately, the ministry does not provide any information on the causes of death in any age range, so it is impossible to determine whether myocarditis or other cardiac conditions played a major role in the higher-than-expected figures.

Further, the number of extra deaths is very small on an absolute basis and could be due to chance, as the ministry explains. Again, though, deaths in vaccinated people should be well below normal in the days following vaccination, not above.

Just another potential red flag about the mRNAs health authorities around the world seem to have no interest in pursuing.